Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Insight into Achieving & Maintaining Target Serum Urate Levels in Gout Patients

Lara C. Pullen, PhD  |  November 11, 2019

The investigators were not able to identify allopurinol start dose or previous allopurinol exposure as factors in achieving or maintaining target serum urate.

“Our study highlights the role of co-morbidities in the achievement of target [serum urate level] with allopurinol,” write the authors. “The presence of two or more co-morbidities was independently associated with 20% lower odds of maintaining target [serum urate level of less than] 6 mg/dL compared with no co-morbidities.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The authors conclude that a multifaceted approach with several policy initiatives will be necessary to address these factors that appear to influence the effectiveness of allopurinol.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Singh JA, Yang S, Saag KG. Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in the National Veterans Administration gout cohort. J Rheumatol. 2019 Aug 15. pii: jrheum.190522. [Epub ahead of print]

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolGoutserum urate levels

Related Articles

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021’

    November 10, 2021

    Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.

    New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

    New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

    March 18, 2019

    Results of a recent study in Arthritis & Rheumatology fail to clarify whether urate-lowering therapies may potentially reduce mortality risk in patients with gout.1 The study also underscores the fact that many physicians are not following the ACR guideline to help their patients achieve target serum urate levels. Partly because of this, it remains unclear…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences